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Medical genetics typically entails the detailed characterization of a patient’s phenotypes followed
by genotyping to discover the responsible gene or mutation. Here, we propose that the systematic
discovery of genetic variants associatedwith complex diseases such as autism are progressing to a
point where a reverse strategy may be fruitful in assigning the pathogenic effects of many different
genes and in determining whether particular genotypes manifest as clinically recognizable pheno-
types. This ‘‘genotype-first’’ approach for complex disease necessitates the development of large,
highly integrated networks of researchers, clinicians, and patient families, with the promise of
improved therapies for subsets of patients.The genetic study of complex disease has
historically been difficult, meeting with
limited success and often even fewer
therapeutic advances in patient care. Un-
like Mendelian disorders, complex dis-
ease is defined as a phenotype that is
not caused by a single gene mutation
but, rather, by many individual gene
events, with a significant contribution
from environmental factors. The nature
of complex genetic diseasemakes patient
care difficult, as a clinician may never see
two individuals with the same gene muta-
tion and, therefore, the same underlying
genetic etiology. Classical approaches
to the study of complex disease have
identified patientswith similar phenotypes
and have attempted to identify the com-
mon causative mutation for this pheno-
type using association studies. Though
there have been numerous loci reported
over the last 10 years, in most cases,
much of the heritability of complex dis-
ease remains unresolved (Manolio et al.,
2009). The number of success stories
for complex neurocognitive and neuro-
behavioral disease are even fewer, with
enormous numbers of patients (>30,000)
being required to discover a small fraction
of the genetic risk using genome-wide
association study (GWAS) approaches
(McCarroll and Hyman, 2013). Complex
neurodevelopmental disorders, such as
autism, schizophrenia, bipolar disorder,872 Cell 156, February 27, 2014 ª2014 Elsevintellectual disability (ID), and devel-
opmental delay (DD), require better
approaches to link genotype to pheno-
type. In this Essay, we focus on autism
spectrum disorder (ASD)—a highly com-
plex neurodevelopmental disease with a
range of phenotypes and a large patient
base—and propose a gene-centric meth-
odology to model a streamlined approach
for subtyping autism starting with the
genotype (Schulze and McMahon, 2004).
The explosion of data from recent
exome studies (Iossifov et al., 2012; Neale
et al., 2012; O’Roak et al., 2012b; Sanders
et al., 2012) and earlier work on large copy
number variants (CNVs) (de Vries et al.,
2005; Sebat et al., 2007; Sharp et al.,
2006) have emphasized the importance
of sporadic truncating mutations in ASD,
revealing a surprising level of genetic het-
erogeneity among patients. From these
data, it has been estimated that >500
distinct loci may be related to disease
etiology in ASD, assuming a model of
sporadic protein-encoding mutations.
Interestingly, more than two decades
ago, Percy postulated that a ‘‘very wide
variety of autistic syndromes depending
on underlying etiology’’ may exist based
on his observation that a significant frac-
tion of individuals with fragile X, Rett,
and tuberous sclerosis syndromes could
be classified as having autistic features
(Percy et al., 1990). Whereas traditionalier Inc.genetics approaches were entirely under-
powered to detect small subpopulations
of autism with a common mutant gene,
the advent of next-generation sequencing
technology has made it possible to begin
to systematically classify genetic sub-
types of ASD and, further, to ask whether
these define specific clinical subtypes of
ASD. For the purpose of this Essay, we
will define a ‘‘genetic subtype’’ as a gene
in which recurrent mutations show an
excess of burden in patients versus con-
trols. This is distinguished from a ‘‘molec-
ular subtype’’ that constitutes a group of
genetic subtypes that are linked together
in a common pathway (coexpression,
protein-protein interaction network, etc.)
(O’Roak et al., 2012b).
The extreme genetic heterogeneity
exemplified by autism, we believe, re-
quires a shift in the approach to studying
the genetics of complex neurological
disease. Instead of comprehensive and
exhaustive phenotyping as the first step
to reducing genetic heterogeneity, we
propose to leverage technology to genet-
ically classify subtypes of disease among
patients in whom clinical recontact is
possible. We outline three logical steps
in characterizing genetic subtypes from
the perspective of autism: (1) candidate
discovery and determination of pathoge-
nicity, (2) comprehensive clinical pheno-
typing, and (3) resolution of genetic
Figure 1. Schematic of Genotype-First Approach for ASD
(A–C) Following complex neurodevelopmental disease diagnosis in the clinic, step one is to apply next-
generation sequencing (exome or whole-genome) to identify high-impact rare or de novo variants that
exist(s) in an individual. Through screening of many individuals, recurrent mutations in a gene or locus are
identified with a general diagnosis of ASD or DD. These candidates are selected for targeted resequencing
using high-throughput, cost-effective technologies. Molecular inversion probe (MIP) technology, for
example, applied to thousands of individuals with ASD or DD identifies genes with an excess mutational
burden in probands when compared to controls. Such genes are most likely to contribute to disease
etiology and represent future targets for therapeutic intervention. Families with these gene mutations are
recontacted and brought back to the clinic for more comprehensive phenotyping (step two). There will be
those genes that have a common, strong, single clinical phenotype (A); however, these will likely be rare.
There may be those individual genotypes that all affect the same functional pathway (molecular subtypes)
and result in similar or potentially opposing phenotypes (e.g., macrocephaly versus microcephaly) (B).
Some mutations even within the same gene, however, may have multiple associated clinical phenotypes
(C), suggesting high variability in the type of mutation relative to its gene function and/or incomplete
penetrance. The latter especially will require more in-depth study for genetic background effects (step
three). This approach will group patients foremost based on genotypes or sets of mutated genes. Larger
groups of patients with the same presumptive genetic etiology are re-examined to identify specific clinical
phenotypes, with the goal of improving diagnosis, patient care, and management.background effects (Figure 1). There are
alternative approaches to identifying sub-
types of ASD, including the modeling of
existing behavioral data sets or the anal-
ysis of clinical records to derive clusters
of patients with ASD (Bitsika et al., 2008;
Doshi-Velez et al., 2014; Sacco et al.,
2012), that will continue to contribute to
subtype identification. However, we
have now been able to identify recurrent
rare disruptive mutations in the same
gene to the point of statistical significance
in ASD patients (O’Roak et al., 2012a),
and this is just the beginning. As more
patients are analyzed by this approach,
we will begin to identify the true scope of
genetic subtypes in ASD. The reasonable
next step will be to ask whether these
genetic subtypes define distinct clinical
entities. If so, this clears a path for future
functional studies and therapeutic devel-
opment, as well as patient support groups
based on common subtypes of ASD.Gene Discovery and Pathogenicity
The most important step is to identify the
genes and the most highly penetrant
mutations first. For genetically heteroge-
neous diseases such as autism, this
requires an unprecedented scale of coor-
dination and sample collection. Exome
sequencing of patients with ASD is well
underway, with the exomes of >10,000
patients expected to be completed in
the next year (Buxbaum et al., 2012).
Recent work has already demonstrated
the unequivocal importance of putative
loss-of-function mutations, at least in the
case of ID and simplex autism (Veltman
and Brunner, 2012). Nevertheless, the
biological significance of most de novo
mutations discovered as part of exome
and genome sequencing projects is un-
certain. The locus heterogeneity necessi-
tates resequencing a much larger cohort
to prove pathogenicity. If CNV studies
are to be a guide, tens of thousands ofCell 156,patients will be required to achieve statis-
tical significance for specific loci. Patients
with ID and DD represent a rich resource
for the discovery and validation of addi-
tional de novo ASD mutations, as more
than an estimated 50% of individuals
with clinically defined ASD are also intel-
lectually impaired (La Malfa et al., 2004;
Matson and Shoemaker, 2009). Indeed,
more than half of the recurrent truncating
mutations discovered in the Simons Sim-
plex Collection (SSC) occurred among in-
dividuals with an IQ of <70 (O’Roak et al.,
2012a). Similarly, the majority of the most
strongly associated ‘‘autism’’ CNVs (e.g.,
16p11.2) are also prevalent among chil-
dren with ID and DD (Girirajan et al.,
2013; Sanders et al., 2011), highlighting
the shared genetic etiology underlying
these neurodevelopmental disorders.
Dealing with such a large number of
patients poses significant hurdles. First,
it requires a high-throughput, cost-effec-
tive resequencing strategy. Rare and pri-
vate variants such as these cannot be
readily imputed using GWAS approaches
but, rather, must be directly detected—
as is the case for CNVs associated with
ASD. Molecular inversion probes (MIPs)
provide one such approach to rapidly
resequence candidate genes with high
sensitivity and specificity (Turner et al.,
2009). Current estimates indicate that,
with limited starting material, it is possible
to resequence 50 genes for less than $1
per gene/sample (O’Roak et al., 2012a).
The second major hurdle is the samples
themselves. Most individual sample col-
lections are inadequate and therefore too
underpowered to achieve statistical sig-
nificance. This realization has led to the
formation of consortia such as the Autism
Sequencing Consortium (ASC) (Buxbaum
et al., 2012) and the Autism Spectrum/
Intellectual Disability network (ASID),
representing groups of researchers and
clinicians that have agreed in principle to
share samples, technology, and sequenc-
ing results to pinpoint genetic risk factors
much more quickly (Figure 2). Though
this collaboration is an important step
forward, simply merging sample collec-
tions or sequencing results in a case-
control design remains insufficient.
As sequencing becomes much more
routine, more integrated patient-clinician-
researcher networks dedicated to a
specific molecular lesion should beFebruary 27, 2014 ª2014 Elsevier Inc. 873
Figure 2. The Autism Spectrum/Intellectual Disability Network
The Autism Spectrum/Intellectual Disability network (ASID), composed of
21 basic research and clinical laboratories from around the world, has
assembled >15,000 patients for gene resequencing. The network is broader
than the Autism Sequencing Consortium (ASC) in that it considers patients
with ASD, ID, epilepsy, or DD due to their comorbidity. It emphasizes collec-
tions where parental DNA is available and where patient recontact is possible
to accurately resolve phenotype-genotype correlations. The network includes
clinical research labs across the world (blue squares) and labs in the USA (red
dots; illustration courtesy of SFARI) that recruit families as part of the SSC,
where patient recontact has now been made possible after extensive IRB
review. Subsets of patients with mutations in a common gene are being re-
assessed to determine whether the mutation defines a clinical subtype.envisioned, similar to what
has already begun to occur
with specific CNVs through
the Simons Variation in
Individuals (VIP) Project (Con-
sortium, 2012) and Unique
(http://www.rarechromo.org/
html/home.asp) models. The
Simons VIP focuses on the
extensive study of indivi-
duals with specific recurrent
CNVs that increase the risk
for developmental disorders.
The project includes the
development of patient com-
munities through social net-
working and education built
around an online portal. The
initial CNV addressed was
16p11.2, and additional
CNVs have since been
included in the project (e.g.,
1q21.1), with more CNVs
scheduled. Families engaged
in the community are alsooffered the opportunity to participate in
research that includes comprehensive
behavioral phenotyping, medical exami-
nation, and imaging assessments con-
ducted in a clinical context. The combi-
nation of an online portal, extensive
recruitment, multisite collaboration, and
rapid data sharing policies has enhanced
the pace of understanding of deletions
and duplication at the 16p11.2 locus in
a very short amount of time. UNIQUE is
an online portal focused on education,
awareness, and support for families
with rare chromosomal disorders.
Through this online presence, families
and practitioners are connected so that
research findings are translated, educa-
tion is provided, and families are pre-
sented with opportunities for research
participation. Both Simons VIP and
UNIQUE provide needed resources and
education for patients and families while
at the same time allowing for the collec-
tion of genetically defined populations
of patients for advancing scientific un-
derstanding.
The final hurdle to establishing patho-
genicity is the evaluation of suitable
controls. Some of the most interesting
mutations may lurk in the general popula-
tion at low frequency. Well-phenotyped
controls, in large numbers, are even
more limited than patient cohorts. The874 Cell 156, February 27, 2014 ª2014 Elsevad hoc use of ‘‘population average’’ con-
trols from exome sequencing projects
(e.g., the Exome Sequencing Project
[ESP]), as opposed to disease-specific
controls in which DNA and individuals
can be revisited for additional analyses,
is problematic.
Comprehensive Clinical
Phenotyping
Once specific genes have been identified
with recurrent and/or structural muta-
tions, a critical next step is to explore
the phenotypes associated with sporadic
mutations. This requires a reassessment
at the clinical level once the mutations
are discovered because the number of
genes that are responsible for autism ap-
pears to be so vast. Moreover, it is quite
likely that exome or genome sequencing
will become a routine diagnostic inevi-
tably incorporated into the electronic
medical record, and once a case report
is established, clinical evaluation can pro-
ceed in a more-directed fashion. There
should be two objectives: (1) define
clinical subtypes of ASD based on a
rigorous examination of different cases
with the same mutated gene and (2)
assess whether the de novo mutations
are highly penetrant. Although rare, this
approach has identified some CNVs
(e.g., 17q21.31 and 15q24.3 deletions)ier Inc.that appear to be necessary
and sufficient for disease
(i.e., all cases are de novo
and no instances of the
mutation have been found
in large surveys of the
general population). If >500
genes are responsible for
ASD—each a different gene
in a specific family—even the
specialist focused on ASD
would unlikely see the same
genetic cause twice in 25
years of practice. Next-gener-
ation sequencing provides
the requisite sieve, allowing
the needles in the haystack to
be sorted at the molecular
level down to a handful of high-
ly relevant clinical phenotypes.
Only through a genotype-first
approach is there the un-
precedented opportunity to
bring together 10–20 pa-
tients with a common geneticetiology for rigorous and detailed
phenotyping. Thus, in this investigative
paradigm, enabled by next-generation
sequencing, phenotype assessment be-
comes secondary to mutation discovery
but also more important (Schulze and
McMahon, 2004; Hennekam and Bie-
secker, 2012).
Recontact and longitudinal assessment
via large consortia is key to this dissec-
tion. Ironically, most existing cohorts,
even those that are well phenotyped and
supported for future work (e.g., the
SSC), are not collected in such a way
that patient recontact is immediately
possible. Recontact with consortia partic-
ipants can be established but requires
significant time and coordination with
institutional review boards (IRBs) in order
to ensure that appropriate attention to
research subjects’ wishes regarding pri-
vacy and contact are maintained
(Figure 2). Nevertheless, even with limited
phenotype data, important genotype-
phenotype data are beginning to emerge.
For example, the recent characterization
of patients with recurrent disruptive muta-
tions in the b-catenin/Wnt-signaling
pathway identified a subset with macro-
cephaly (e.g., PTEN) and a subset with
microcephaly (e.g., DYRK1A) (Figure 3).
Although these results are preliminary,
owing to the small number of individuals
Figure 3. Potential Genetic Definition of Autism Subtypes
Individuals with autism have been described as having an increased head circumference size (HCZ)
distribution (Courchesne et al., 2003). This is observed among ASD probands of the SSC where HCZ is
positively skewed (blue arrow) when compared to a normal distribution (left). Subselecting patients (red)
with de novo mutations in the b-catenin/Wnt-signaling network (Iossifov et al., 2012; Neale et al., 2012;
O’Roak et al., 2012b; Sanders et al., 2012)—defined as those de novo proband events that cluster around
the central CTNNB1 node using either STRING or Ingenuity Pathway Analysis enrichment (n = 26
individuals)—further transforms this into a bimodal distribution (right), suggesting reciprocal macro-
cephaly and microcephaly associated with de novo mutations in this pathway.and the need to control for additional
covariates, the data suggest that the
extreme genetic heterogeneity (i.e., >500
different genes) may be reduced to
much smaller subsets of biologically
related networks (coexpression or protein
networks) with restricted phenotypic pre-
sentation (i.e., molecular subtypes). This
pathway and the genes associated with
it may be an important first step in identi-
fying molecular and clinical subtypes of
ASD arising from defects in neural pro-
genitor cell proliferation and apoptosis.
As patients and families are recon-
tacted and engaged in follow-up evalua-
tion, the phenotypic workup of patients
should be intensive and should include a
careful assessment of core behaviors in
the domains of ASD; critical evaluation
of related symptoms and behaviors such
as affective, attentional, or behavioral
challenges; and standardized testing
of cognitive and adaptive functioning. It
should include a standardized assess-
ment of comorbid medical conditions
(e.g., intellectual disability, epilepsy,
neuropsychiatric disease, cancer risk,
etc.), careful review of medical history,
brain imaging, and physical examination
with a focus on dysmorphology. This
approach has been particularly useful in
our ongoing examination of 100 cases of
the 16p11.2 microdeletion, in which we
identified speech sound disorders, motor
coordination impairment, and medicalconcerns such as enuresis and seizures
in a significant fraction of cases. More
generally, patient recontact has been
critical for the identification of new syn-
dromes associated with specific CNVs.
Adding to the challenge is that the pro-
cess needs to be dynamic and iterative.
Namely, index cases (the original families
used to establish the first version of the
working clinical phenotype) will be
required to help establish a set of stan-
dards and checklists that can evolve in
consultation with clinicians, counselors,
and families as additional cases are
discovered.
The genotype-first approach helps to
address the challenges that are inherent
in attempting to carve nature at its joints
based strictly on a behavioral presenta-
tion. A key problem with classifying sub-
types by strict clinical criteria is that
particular manifestations may depend on
a specific point in time in which a patient
is evaluated (Charman et al., 2005; Foun-
tain et al., 2012; LaMalfa et al., 2004; Lord
et al., 2012; McGovern and Sigman, 2005;
Pellicano, 2012). This is especially rele-
vant if ASD is regarded as primarily a
disorder of neurodevelopment. A 2-year-
old with ASD can present remarkably
differently just 1 year later as a function
of a dynamic developmental trajectory.
That is, the same degree or quality of
impairment in social communication with
peers can appear significantly differentCell 156,for a 3-year-old preschool child com-
pared to a 6-year-old first-grade student
based on developmental context. The
influence of interactive endogenous and
exogenous factors renders multiple as-
sessments conducted in a developmental
context essential for the accurate behav-
ioral phenotyping of complex neuro-
developmental disorders. Longitudinal
follow-up is thus necessary to define dis-
ease trajectories as the patients age. The
genetic mutation in a key autism gene
provides an objective point of reference
to study and compare such develop-
mental progressions.
Genetic Background Effect and
Phenotypic Heterogeneity
Based on experience with large CNVs, we
anticipate that there will be multiple cate-
gories of highly penetrant mutations that
will constitute the genetic subtypes of
ASD. First, and perhaps the most satis-
fying, will be those mutations that are
most penetrant for disease and associate
with a prescribed set of clinical features
irrespective of the genetic background
(Figure 1A). Such mutations will direct
diagnosis and will drive the definition of
new syndromic forms of autism. However,
the proof for these mutations will ulti-
mately rest on demonstration of enrich-
ment or exclusivity of this type of mutation
in patients with a particular subset of
features. Most mutations will, unfortu-
nately, not be this simple. A second
category of mutations may be those
linked to each other through a common
protein interaction pathway or functional
network, leading to phenotypic mani-
festations that are virtually indistinguish-
able at a clinical level (Figure 1B). For
example, there are suggestions that de
novo mutations in different genes within
the b-catenin/Wnt-signaling pathway will
define a subset of microcephalic and
macrocephalic individuals with ASD
(Figure 3). Although more complex, these
mutations may also define syndromic
forms of ASD and drive patient care
when identified. There will still be muta-
tions in other genes and their associated
binding partners that appear, on first
blush, hopelessly phenotypically variable
and/or incompletely penetrant. Mutations
in ARID1B, for example, have been found
in patients with Coffin-Siris syndrome,
syndromic ID, and ASD (Halgren et al.,February 27, 2014 ª2014 Elsevier Inc. 875
2012; Santen et al., 2013). In the end,
there will undoubtedly remain many
genes whose mutation will lead to either
clinically subtle or variable phenotypes,
limiting any immediate diagnostic value
to the approach that we have described.
However, even in such cases, under-
standing the molecular basis of disease
will ultimately drive more precise thera-
peutic intervention.
Even in the cases of apparent gene plei-
otropy, we predict that, as larger and
larger numbers of patients are studied,
smaller subtypes will emerge, as has
begun to be observed with certain vari-
able expressive CNVs, wherein a particu-
larly sensitive genetic background may
give way to disease due to additional ge-
netic modifiers that would otherwise be
genetically silent. In the case of the 1q21
deletion, for instance, a number of sub-
categories began to emerge (e.g., multi-
ple cases with cataracts, others with
structural heart defects, and still others
with cognitive deficits) after a larger num-
ber of patients were identified (Mefford
et al., 2008). We argue that grouping on
the ‘‘primary’’ mutation (e.g., 1q21 dele-
tion) enables a more-directed study on
the full extent of variable expressivity for
that lesion where subsets of clinical
manifestation may become apparent.
The genotype-first approach provides
the means to explore both pleiotropy
and variable expressivity (Figure 1C). For
variants such as these, it will be critical
to understand the potential effect of mod-
ifiers on the phenotype. Although we
may never have the statistical power to
identify a single genetic modifier at a
specific locus, signal may become
apparent in the aggregate. For example,
a higher burden of CNVs of both known
and unknown pathogenic significance in
aggregate compound the severity of
disease presentation for patients with
the 16p12.1 microdeletion (Girirajan
et al., 2012). Such information is ultimately
critical for practical management of dis-
ease and patient counseling.
We stress that a significant association
signal and a large effect size are not proof
positive of causality. Indeed, there is a
disturbing trend of excluding patient
DNA from further analysis due to the pres-
ence of a putative CNV or loss-of-function
mutation in a gene that is presumed to be
the primary cause of disease. We argue876 Cell 156, February 27, 2014 ª2014 Elsevthat such samples should be subjected
instead to more intensive genetic scrutiny
to understand the genetic basis of the
phenotypic variability and the com-
plete spectrum of potentially deleterious
alleles. Full-genome sequencing, for
example, will lead to the characterization
of small CNVs within complex regions of
the genome and to the discovery of muta-
tions in conserved regulatory regions.
Suchmutationsmay provide the evidence
needed to explain phenotypic variability in
such cases. Studying such mutations in
the context of families—i.e., genomic
sequencing of unaffected transmitting
parents—may provide some important
clues as well. Numerous lines of evidence
argue that the genetic background is key
for such phenotypic variability and that
multiple mutations in different genes
may compound to result in a specific
outcome (Girirajan and Eichler, 2010;
Schaaf et al., 2011). The important point
here is that patients grouped by a com-
mon genetic lesion represent, once again,
an objective starting point to begin to
assess the effect of other modifiers. This
includes not only genetic but epigenetic
and environmental factors that may affect
the phenotypic outcome of a particular
mutation and autism.
Conclusion
With sequencing becoming increasingly
cheaper as well as the preferred frontline
diagnostic test (Johnson et al., 2011),
researchers are now in the position to
effectively break down the umbrella of
ASD. We propose that defining molecular
subtypes will serve as a superior class-
ifier compared to ever-changing psy-
chiatric nosological definitions (e.g.,
DSM-5 [AmericanPsychiatric Association,
2013]). Indeed, NIMH has made a dedi-
cated commitment to addressing limita-
tions in diagnostic boundaries defined by
consensus through the establishment of
the Research Domain Criteria for clinical
research (Insel et al., 2010). There is a
pressing need to systematically prioritize
gene-disruptive events and to rapidly and
cost-effectively resequence candidates in
many thousands of individuals and con-
trols in the contextof the families to identify
high-impact risk factors. Because there is
so much overlap among ASD, ID, and epi-
lepsy, broader consortia that consider pa-
tients outside of the strict ASD diagnosisier Inc.should be envisioned. Patients with com-
mon genetic etiology should be revaluated
for common clinical features no matter
their initial diagnosis (e.g., ASD, ID,
epilepsy). This has the benefit of control-
ling for ascertainment bias and dis-
covering truly disease-specific genes in
addition tomore broadly defined neurode-
velopmental disease genes.
This genotype-first perspective also
offers both short- and long-term benefits
to patients. The identification of genetic
subtypes of ASD (especially those muta-
tions deemed most penetrant) provides
a medium to rapidly network families,
researchers, and clinicians. For families,
this will translate into better diagnosis,
counseling, and the formation of patient-
driven support groups through meetings
and interactive websites that link families
across the world who have children
with a common genetic etiology. Such
networks, if properly implemented, can
effectively drive research and advance
clinical understanding of phenotype-
genotype correlations and may further
spawn the formation of foundations and
dedicated research endeavors (e.g., the
Simons VIP).
From a longer-term perspective, the
genotype-first approach that we propose
will lead to genetic classification of ASD
subtypes and may be more broadly
applied to complex diseases, such as
schizophrenia, ID, DD, and bipolar disor-
der. There is emerging evidence that
such seemingly diverse clinical diagnoses
may be, in some cases, genetically linked.
The discovery of mutations, genes, and
pathways across such diverse diseases
not only promises to revolutionize our
biological understanding but also may
lead to the development of therapies
focused on the mutation as opposed to
a nosological definition. This holds the
promise of better clinical intervention and
a full realization of precision medicine.ACKNOWLEDGMENTS
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